Russia may be faced with a shortage of drugs in the future, due to the forthcoming transition to a new system of drug labeling that may lead to huge interruption in medicines supplies to the country, according to an official spokesman of the Russian Ministry of Health, reports The Pharma Letter’s local correspondent.
By 2019, all drug importers and producers operating in Russia must begin labeling drugs using a new technology that requires producers to make certain investments in its introduction, the amount of which is estimated at "several million dollars for a single plant."
In addition, starting from 2019, all producers should be connected to the new information system, which is operated by the Russian Federal Tax Service (FTS).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze